Abstract: The invention relates to short RVG derived peptides for use in delivering therapeutic agents across the blood brain barrier and to target cells, for example those cells in the central nervous system. The invention provides method and compositions to treat diseases, such as neurodegenerative diseases, with therapeutic agents associated with targeting peptides.

Abstract: The present invention describes the use of the Chinese medicinal compounds ginsenoside RB1, dihydromyricetin and salvianohc acid B, for use in diagnosing, monitoring and treating synucleinopathies, such as Parkinson's disease, in patients.

Abstract: The invention relates to an antibody or fragment thereof and a method of treatment and/or diagnosis using the antibody. The antibody or fragment thereof binds to human alpha-synuclein including monomeric, oligomeric and fibril forms of alpha-synuclein; is not cross reactive with beta-synuclein or gamma synuclein; specifically binds human alpha-synuclein and is not cross reactive with rat or mouse alpha-synuclein; binds nitrated, oxidized and phosphorylated forms of alpha-synuclein; and binds an epitope of human alpha synuclein comprising the sequence LEDMPVDPDNEAYE (SEQ ID NO:2). A method for diagnosing a neurodegenerative disease associated with alpha-synuclein or of detecting alpha-synuclein, comprises adding the antibody or fragment thereof to a biological sample from a subject, and detecting the presence or absence of a complex formed between alpha-synuclein and the antibody or fragment.

Abstract: The invention relates to an antibody or fragment thereof and to a method of treatment and/or diagnosis using the antibody or fragment thereof. The antibody or fragment thereof is capable of binding to human alpha-synuclein, including monomeric, oligomeric and fibril forms of alpha-synuclein; is cross reactive with beta-synuclein and gamma synuclein; and binds an epitope of human alpha synuclein comprising the sequence MPSEEGYQDYEPEA (SEQ ID NO:2). A method for diagnosing a neurodegenerative disease associated with alpha-synuclein or of detecting alpha-synuclein comprises adding the antibody or fragment thereof to a biological sample from a subject, and detecting the presence or absence of a complex formed between alpha-synuclein and the antibody or fragment.

Abstract: The invention relates to an antibody or fragment thereof and the use of the antibody in a method of treatment and/or diagnosis. The antibody or fragment thereof specifically binds to alpha-synuclein, including monomeric, oligomeric and fibril forms of alpha-synuclein; is not cross reactive with beta-synuclein or gamma-synuclein; specifically binds human, rat and mouse alpha-synuclein; binds nitrated, oxidized and phosphorylated forms of alpha-synuclein; and binds an epitope of human alpha synuclein comprising the sequence MPSEEGYQDYEPEA (SEQ ID NO:2). The method for diagnosing a neurodegenerative disease associated with alpha-synuclein or for detecting alpha-synuclein, comprises adding the antibody or fragment thereof to a biological sample from a subject, and detecting the presence or absence of a complex formed between alpha-synuclein and the antibody or fragment.

Abstract: The invention relates to short RVG derived peptides for use in delivering therapeutic agents across the blood brain barrier and to target cells, for example those cells in the central nervous system. The invention provides method and compositions to treat diseases, such as neurodegenerative diseases, with therapeutic agents associated with targeting peptides.

Abstract: The present invention describes the use of the Chinese medicinal compounds ginsenoside RB1, dihydromyricetin and salvianohc acid B, for use in diagnosing, monitoring and treating synucleinopathies, such as Parkinson's disease, in patients.